Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Thomas Frohlich | Mar 11, 2014 at 6:31 AM EDT

The Fattest States in America

Based on figures from the Gallup-Healthways Well-Being Index, 24/7 Wall St. reviewed the 10 states with the highest obesity rates.…

Paul Ausick | Mar 10, 2014 at 9:45 AM EDT

Health Insurance Satisfaction Slashed by Coverage Issues

ThinkstockMore than 40% of health insurance plan customers were dissatisfied with their plan’s coverage, according to the latest data from…

Trey Thoelcke | Mar 10, 2014 at 9:05 AM EDT

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

In a new research report, Cowen analysts posted a list of some of the top new datapoints cited at the…

Jon C. Ogg | Mar 8, 2014 at 8:01 AM EST

Low-Priced Biotech Stocks That Could Double (or More)

ThinkstockThe latter part of the week was difficult for the biotech and specialty pharmaceutical sector. Unsettling news out of Washington,…

Jon C. Ogg | Mar 7, 2014 at 10:30 AM EST

Biomet Is Coming Public via IPO, Again

ThinkstockWhat would appear to be an obscure initial public offering from LVB Acquisition Inc. is much more important than it…

Trey Thoelcke | Mar 7, 2014 at 9:00 AM EST

Biotech Stocks to Buy After the Pullback

The biotech and specialty pharmaceutical groups got hit hard Thursday for a variety of reasons. The largest of which the…

Jon C. Ogg | Mar 6, 2014 at 3:43 PM EST

Analyst Still Sees Dendreon Worth Only $1

ThinkstockDendreon Corp. (NASDAQ: DNDN) remains a company in trouble. The post-earnings jump looked promising and investors probably took some comfort…

cgblaine22 | Mar 6, 2014 at 7:35 AM EST

Peregrine Move Looks Sustainable, at Least for Now

Peregrine Pharmaceuticals may be on the verge of something big with its anticancer drugs. The shares soared almost 50% on…

Trey Thoelcke | Mar 4, 2014 at 8:50 AM EST

Merrill Lynch’s Top Health Care Stocks to Buy Now

Merrill Lynch likes the health care sector and has made no secret that they think that it can continue to…

cgblaine22 | Mar 3, 2014 at 10:55 AM EST

Dendreon Finds New, Long Overdue Lifeblood

Shares of Dendreon moved higher Monday after the biotech company said it will start to market Provenge, its prostate-cancer drug,…

Jon C. Ogg | Mar 1, 2014 at 10:39 AM EST

Top Biotech Stocks Under $5 With Huge Potential Upside

ThinkstockWith the top stocks in the market exploding in price due to the recent rally, we wanted to scan across…

Jon C. Ogg | Feb 28, 2014 at 9:55 AM EST

A Punishing Compugen Secondary Offering to Raise Cash

Compugen is raising close to $60 million in a secondary offering, but at a punishing price to any new shareholders…

Jon C. Ogg | Feb 27, 2014 at 10:40 AM EST

Can Aegerion Still Rise 70%?

Merrill Lynch issued a note on Aegerion Pharmaceuticals in the wake of its earnings report that both maintained a Buy…

Trey Thoelcke | Feb 27, 2014 at 7:00 AM EST

Short Sellers Return to Biotech Stocks

After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical…

Jon C. Ogg | Feb 26, 2014 at 3:38 PM EST

Best Performing IPOs of 2014 Are in Biotech

ThinkstockThe initial public offering market has been rather strong in 2014. After we recently featured our Top 10 IPOs to…

1 … 292 293 294 295 296 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

The Fattest States in America

Health Insurance Satisfaction Slashed by Coverage Issues

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

Low-Priced Biotech Stocks That Could Double (or More)

Biomet Is Coming Public via IPO, Again

Biotech Stocks to Buy After the Pullback

Analyst Still Sees Dendreon Worth Only $1

Peregrine Move Looks Sustainable, at Least for Now

Merrill Lynch’s Top Health Care Stocks to Buy Now

Dendreon Finds New, Long Overdue Lifeblood

Top Biotech Stocks Under $5 With Huge Potential Upside

A Punishing Compugen Secondary Offering to Raise Cash

Can Aegerion Still Rise 70%?

Short Sellers Return to Biotech Stocks

Best Performing IPOs of 2014 Are in Biotech

His Military Pension Didn’t Shrink His Social Security. His New Defense-Plant Paycheck Could.

Which Crypto Do AI Models Say to Buy Right Now: Bitcoin, Ethereum, or XRP?

This 1 Number Says Michael Saylor’s Bitcoin Sales Are About to End

His Military Pension Didn't Shrink His Social Security. His New Defense-Plant Paycheck Could.

A Retired Couple Can Pull About $47,500 From Their IRAs This Year and Pay $0 Federal Tax. Most Leave the Free Space Unused.

His Military Pension Didn’t Shrink His Social Security. His New Defense-Plant Paycheck Could.

Which Crypto Do AI Models Say to Buy Right Now: Bitcoin, Ethereum, or XRP?

Health and Healthcare Articles

All Health and Healthcare Articles

The Fattest States in America

Health Insurance Satisfaction Slashed by Coverage Issues

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

Low-Priced Biotech Stocks That Could Double (or More)

Biomet Is Coming Public via IPO, Again

Biotech Stocks to Buy After the Pullback

Analyst Still Sees Dendreon Worth Only $1

Peregrine Move Looks Sustainable, at Least for Now

Merrill Lynch’s Top Health Care Stocks to Buy Now

Dendreon Finds New, Long Overdue Lifeblood

Top Biotech Stocks Under $5 With Huge Potential Upside

A Punishing Compugen Secondary Offering to Raise Cash

Can Aegerion Still Rise 70%?

Short Sellers Return to Biotech Stocks

Best Performing IPOs of 2014 Are in Biotech

His Military Pension Didn’t Shrink His Social Security. His New Defense-Plant Paycheck Could.

Which Crypto Do AI Models Say to Buy Right Now: Bitcoin, Ethereum, or XRP?

This 1 Number Says Michael Saylor’s Bitcoin Sales Are About to End

Featured Reads

His Military Pension Didn't Shrink His Social Security. His New Defense-Plant Paycheck Could.

A Retired Couple Can Pull About $47,500 From Their IRAs This Year and Pay $0 Federal Tax. Most Leave the Free Space Unused.